| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8218855 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
The addition of panitumumab to CRT with carboplatin and paclitaxel was safe and well tolerated but could not improve pCR rate to the preset criterion of 40%.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Sil MD, Mark I. MD, PhD, Maarten C. MD, PhD, Jacques J.G.H.M. MD, PhD, Hans J. MD, PhD, Ellen MD, PhD, Hanneke W.M. MD, PhD, Dick J. MD, PhD, Jean H.G. MD, PhD, Sybren L. MD, PhD, Johanna W. MD, PhD,